First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)
首次人体 I 期研究,评估 OX40 激动剂 GSK3174998 与或不与帕博利珠单抗联合治疗特定晚期实体瘤患者的疗效 (ENGAGE-1)
期刊:Journal for ImmunoTherapy of Cancer
影响因子:10.6
doi:10.1136/jitc-2022-005301
Postel-Vinay, Sophie; Lam, Vincent K; Ros, Willeke; Bauer, Todd M; Hansen, Aaron R; Cho, Daniel C; Stephen Hodi, F; Schellens, Jan H M; Litton, Jennifer K; Aspeslagh, Sandrine; Autio, Karen A; Opdam, Frans L; McKean, Meredith; Somaiah, Neeta; Champiat, Stephane; Altan, Mehmet; Spreafico, Anna; Rahma, Osama; Paul, Elaine M; Ahlers, Christoph M; Zhou, Helen; Struemper, Herbert; Gorman, Shelby A; Watmuff, Maura; Yablonski, Kaitlin M; Yanamandra, Niranjan; Chisamore, Michael J; Schmidt, Emmett V; Hoos, Axel; Marabelle, Aurelien; Weber, Jeffrey S; Heymach, John V